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Conclusions: DREAMS shows excellent safety and efficacy data up to 2 years in cohort
1 of the BIOSOLVE-I trial. Multi-modality imaging documented the absorption process
and the uncaging aspect of this device already at 6 months.
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Background: The DESolveTM Myolimus-Eluting Bioresorbable Coronary Scaffold
(Elixir Medical Corporation, Sunnyvale, CA) is a novel bioresorbable vascular scaffold
device that combines a PLLA-based scaffold coated with a potent antiproliferative
sirolimus analog agent Myolimus (3 mcg per mm of scaffold length).
Methods: A total of 15 patients with single de novo coronary artery lesions 14mm in
vessels 2.5-3.75 mm in diameter were enrolled in this prospective, multi-center,
single-arm, first-in-man study, and underwent serial angiographic studies at baseline/
index and 6 months follow-up. Primary endpoint was angiographic in-scaffold late lumen
loss, as determined by quantitative coronary angiography (QCA) analysis performed by
an independent angiographci core laboratory.
Results: Overall, 14 patients/lesions were available for paired analysis. The Right
coronary artery was the most prevalent lesion location (43%) and lesion class according
to the ACC/AHA classification demonstrated type A in 36%, type B1 in 29% and type B2
in (36%). Baseline QCA showed mean lesion length, reference diameter (RD), minimum
lumen diameter (MLD) and % diameter stenosis (DS) of 8.952.64mm, 2.650.32mm,
0.810.29mm and 70.010.5%, respectively. During procedure, predilatation was
performed in 93%, postdilatation was performed in 29%, and final TIMI flow was
achieved in 100%. Final and 6-month follow-up QCA analyses are shown in the Table.
Overall, there was only 1 case of in-segment binary restenosis, which involved the
proximal edge outside the scaffold.
Variable In-Scaffold (N14)
Final
- RD, mm 2.770.25
- MLD, mm 2.600.19
- % DS 8.17.9
- Acute gain, mm 1.790.39
Follow-up at 6 months
- RD, mm
- MLD, mm 2.410.28
- % DS 12.611.4
- Late lumen loss, mm 0.190.19
Conclusions: The DESolve device demonstrated excellent performance in non-complex
coronary lesions including high acute gain and optimal expansion at postprocedure as
demonstrated by the low final %DS. At 6-month follow-up, there was relatively low
in-scaffold late lumen loss (0.19mm), suggesting efficacy of this new technology on
inhibiting neointimal hyperplasia.
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Background: Side branch occlusion (SBO) contributes to the periprocedural myocardial
infarction (MI), which has been associated with unfavorable late clinical outcomes.
However, the incidence and acute clinical outcomes of SBO after bioresorbable vascular
scaffold (BVS) implantation has been unexplored.
Methods: Amongst consecutive 469 patients who were enrolled in the ABSORB-
EXTEND single-arm trial from January 2010 to January 2012, a total of 1127 side
branches in 435 patients were evaluated. Although major side branches  2 mm in
diameter was excluded per protocol, any visible side branches originating within
to-be-scaffolded segment or its 5 mm-proximal and -distal margins were included in the
angiographic assessment. SBO was defined as a reduction in thrombolysis in myocardial
infarction (TIMI) flow to grade 0 or 1.
Results: Pre-procedure reference vessel diameter (RVD) and percent diameter stenosis
were 2.62 mm and 58.6 % in the main vessel, and 1.18 mm and 20.0 % in the side branch,
respectively. Post-procedure SBO was observed in 67 out of 1127 side branches (5.9 %),
while it was 9 out of 537 side branches with a RVD of  1.0 mm (1.7 %). Amongst 67
occluded side branches, 60 (89.6 %) were originated within the obstruction segment in the
main vessel, which was automatically delineated by quantitative coronary angiography.
Periprocedural Non-Q-wave MI (NQMI) according to the protocol definition was
adjudicated in 5 patients (mean ratio of peak CK and CKMB to upper limit of normal
were 2.82 and 4.61, respectively) amongst 61 patients with the angiographic evidence of
SBO post-procedure (8.2 %).
Clinical events
SBO
(N61)
Non-SBO
(N374)
Relative Risk
(95% CI) p value
In-hospital
events, % (n)
Cardiac death 0.0 (0/61) 0.0 (0/374) N/A N/A
Myocardial
infarction
8.2 (5/61) 0.5 (2/374) 15.3 (3.0, 77.3) 0.001
Q-wave 0.0 (0/61) 0.0 (0/374) N/A N/A
Non-Q-wave 8.2 (5/61) 0.5 (2/374) 15.3 (3.0, 77.3) 0.001
Ischemia driven
target lesion
revascularization
0.0 (0/61) 0.0 (0/374) N/A N/A
Major adverse
cardiac events
8.2 (5/61) 0.5 (2/374) 15.3 (3.0, 77.3) 0.001
30-days events
(%)
Cardiac death 0.0 (0/61) 0.0 (0/357) N/A N/A
Myocardial
infarction
8.2 (5/61) 1.4 (5/357) 5.9 (1.8, 19.6) 0.008
Q-wave 0.0 (0/61) 0.8 (3/357) 0 1
Non-Q-wave 8.2 (5/61) 0.6 (2/357) 14.6 (2.9, 73.7) 0.001
Ischemia driven
target lesion
revascularization
0.0 (0/61) 0.0 (0/357) N/A N/A
Major adverse
cardiac events
8.2 (5/61) 1.4 (5/357) 5.9 (1.8, 19.6) 0.008
SBO, side branch occlusion; N/A, not available. Analysis was performed by
Fisher’s exact test.
In-hospital is defined as hospitalization  7 days post-procedure.
Conclusions: Although 5.9 % of small side branches occluded after BVS implantation,
the incidence of periprocedural MI was quite limited.
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Background: The impact of left main (LM) revascularization with the unrestricted use
of drug-eluting stents (DES) on long-term clinical outcomes is still a matter of debate.
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Moreover, everolimus-eluting stents (EES) have not been compared with early generation
sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) in patients with LM disease.
Methods: Out of 12,339 consecutive patients, 11,941 completed last follow-up. 410
(3.4%) patients that underwent LM treatment (177 treated with EES and 233 with
SES/PES) were compared with 11,531 (96.6%) patients that underwent non-LM treat-
ment (3,924 treated with EES and 7,607 with SES/PES). In addition, clinical outcomes
were stratified by stent type among LM and non-LM patients, respectively. Adjustment
was performed with inverse probability of treatment weighting. Primary endpoint was a
composite of cardiac death, myocardial infarction (MI), and target-vessel revasculariza-
tion (TVR).
Results: At baseline, LM patients were older, had more frequently renal failure,
LVEF30%, cardiogenic shock, and smoking habits, and less frequently ACS compared
with non-LM patients. At 4 years, LM patients had a higher risk of the primary endpoint
compared with non-LM patients (34.7% vs 21.5%; HR 1.83, 95% CI 1.52-2.21). This was
mainly driven by a higher risk of cardiac death (18.9% vs 7.3%; HR 2.96, 95%CI
2.28-3.84), whereas no significant differences were observed for MI (4.7% vs 5.4%; HR
0.93, 95% CI 0.52-1.65) and TVR (17.5% vs 14.0%; HR 1.31, 95% CI 0.99-1.73).
Stratification of the primary endpoint by stent type showed a risk reduction with the use
of EES compared with early generation SES/PES. This risk reduction was numerical
among LM patients (30.2% vs 36.8%; HR 0.90, 95% CI 0.62-1.31) and met statistical
significance among non-LM patients (18.5% vs 23.2%; HR 0.73, 95% CI 0.66-0.81), with
no interaction between EES use and LM treatment (p-interaction0.74).
Conclusions: LM patients have impaired clinical outcomes compared with non-LM
patients during long-term follow-up, mainly due to a higher risk of cardiac death. Absence
of significant interaction between EES use and LM treatment suggests that EES use has
comparable impact on clinical outcomes in LM and non-LM patients.
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Background: Current guidelines recommend coronary artery bypass graft surgery
(CABG) when treating significant de novo LM stenosis; however, percutaneous coronary
intervention (PCI) has a Class IIb indication for unprotected left main coronary artery
(ULMCA). This analysis will compare the 5-year clinical outcomes in PCI- and
CABG-treated LM patients in the SYNTAX trial.
Methods: In the SYNTAX trial, patients (N1800) with left main and/or 3-vessel
coronary artery stenoses were randomized to receive either PCI with TAXUS Express
paclitaxel-eluting stents (PES) or CABG. The unprotected LM cohort (N705) was a
predefined subset.
Results: Four-year MACCE and the composite of death/stroke/MI were similar in
ULMCA- PCI and CABG-treated patients (Table). Stroke was significantly increased in
the CABG group and repeat revascularization was increased in the PCI arm at 4 years
(Table). MACCE was similar between groups in patients with low or intermediate
SYNTAX Scores (0-32: 29.0% vs 27.6%, p0.65) but significantly increased in PCI
patients with high scores (33: 26.3% vs 42.6%, p0.003).
Adverse Event Rates in the LM cohort at 4 years
CABG
(n348)
PCI
(n357)
CABG
(n348)
PCI
(n357)
MACCE 27.8% 33.2% Stroke 4.3% 1.5%
Death/
Stroke/MI
17.7% 17.1% MI 4.8% 7.2%
Death 11.2% 11.4% Repeat
Revascularization
14.6% 23.5%
MACCE: Major adverse cardiac and cerebrovascular events including all-cause
death, stroke, myocardial infarction, repeat revascularization. Time-to-event
rates at 4 years.
p0.05 from log-rank or chi-square test.
Conclusions: At 4 years, no difference in overall MACCE was found between treatment
groups. There was an advantage of PCI in stroke and a reduced need for repeat
revascularization with CABG. SYNTAX and other recent studies of LM disease suggest
that in some patients (those with less complex lesions as defined by low or intermediate
SYNTAX Scores), PCI using drug-eluting stents may be as effective but less invasive than
CABG. CABG should be used for patients with more complex anatomical disease (high
SYNTAX Scores). Five-year data will be available at the time of presentation.
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Background: In patients with severe, multivessel coronary disease, coronary artery
bypass grafting (CABG) has been considered the standard of care. We will present 5-year
outcomes in the 3VD subgroup of patients in SYNTAX.
Methods: SYNTAX is a randomized clinical trial with nested registries. A cardiac
surgeon and interventional cardiologist screened consecutive patients with de novo 3VD
and/or LM disease. After informed consent, the patient was randomized if suitable for
equivalent revascularization with either treatment; otherwise, they were enrolled in a
nested registry. Analysis of the 3VD patient cohort was prespecified.
Results: In the 3VD subgroup at 4 years, MACCE was significantly higher in patients
with percutaneous coronary revascularization (PCI) compared with CABG patients. The
rates of composite death/stroke/MI, death, MI, and repeat revascularization were in-
creased in PCI patients; however, stroke was similar between groups at 4 years (Table).
Partitioning 3VD subgroup patients by SYNTAX Score tercile demonstrated similar
MACCE in patients with low scores (0-22: CABG 24.7% vs PCI 30.4%, p0.27);
whereas both MACCE and mortality were increased in PCI patients with intermediate
scores (23-32: 17.9% vs 33.3%, p0.001 and 6.8% vs 12.7%, p0.048), and with scores
33 (21.2% vs 37.9%, p0.001 and 6.5% vs 14.5%, p0.02). Five-year outcomes will
be available at the time of the presentation.
Adverse Event Rates at 4 years in the 3VD cohort
CABG
(n549)
PCI
(n546)
CABG
(n549)
PCI
(n546)
MACCE 21.0% 33.7% Stroke 3.4% 2.8%
Death/
Stroke/MI
12.6% 18.6% MI 3.3% 9.0%
Death 7.3% 11.9% Repeat
Revascularization
10.2% 22.8%
MACCE: Major adverse cardiac and cerebrovascular events including all-cause
death, stroke, myocardial infarction, repeat revascularization. Time-to-event
rates at 4 years.
p0.05 from log-rank or chi-square test.
Conclusions: This will be the first presentation of the final 5-year outcomes in the 3VD
patient population of SYNTAX. Four-year results suggest that CABG remains the
standard of care for patients with complex lesions (intermediate or high SYNTAX Score).
With less complex disease (low SYNTAX Scores), PCI is an acceptable revascularization
alternative.
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Background: The effectiveness of 1st generation durable polymer drug-eluting stents
comes at the expense of delayed arterial healing and subsequent late adverse events such
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